在预医院创伤性心脏骤停中的上腺素 - 挽救生命还是虚假的希望?
Cordelie E Witt1, David V Shatz2, Bryce R H Robinson3
1Department of Surgery, UCHealth Medical Center of the Rockies, Loveland, Colorado.
Prehospital emergency care
|January 31, 2025
概括
在创伤性心脏骤停中使用上腺素并没有改善存活率,并且在重创伤病例中与更糟糕的结果有关. 这些发现表明需要重新评估当前的创伤性逮捕的医院前协议.
科学领域:
- 紧急医疗 紧急医疗
- 创伤外科 手术 创伤外科
- 心脏病学 心脏病学
背景情况:
- 上腺素是医疗性心脏骤停的标准治疗方法.
- 它在创伤性心脏骤停中的有效性,通常是由低血压,缺氧或心脏功能障碍引起的,是不确定的.
- 在创伤患者中,上腺素的内和血管收缩作用可能是无效的或有害的.
研究的目的:
- 为了研究医院前上腺素给药与创伤性心脏骤停患者的生存结果之间的关联.
- 为了确定上腺素是否改善或恶化不同类型创伤伤害的生存率.
主要方法:
- 一项多中心回顾性队列研究分析了来自1631名创伤患者的数据,这些患者患有医院前心脏骤停.
- 使用或不使用上腺素治疗的患者使用单变量和多变量分析进行了比较.
- 用Poisson和Cox的比例危险模型来评估医院出院后的存活率.
主要成果:
- 在接受上腺素 (5%) 的患者中,与未接受上腺素 (16%) 的患者相比,存活到出院的时间显著降低.
- 上腺素与重创伤患者的生存率明显降低有关,但在穿透创伤方面没有统计差异.
- 多变量分析证实,上腺素与整体和重创伤队伍的生存可能性较低有关.
结论:
- 医院前上腺素的使用与创伤性心脏骤停的存活率改善无关.
- 上腺素与突发创伤性逮捕的劣质结果有关,这表明需要修订协议.
- 这些发现可能会为制定更新的医院前指导方针提供信息,用于管理创伤性心脏骤停.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
722
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
722
Adrenergic Neurons: Neurotransmission
3.3K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.3K
Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
Adrenergic Agonists: Mixed-Action Agents
656
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
656
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528
Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K


